 Connection
David Pollock to Anemia, Sickle Cell
This is a "connection" page, showing publications David Pollock has written about Anemia, Sickle Cell.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.655 |
|
|
|
-
Kasztan M, Fox BM, Speed JS, De Miguel C, Gohar EY, Townes TM, Kutlar A, Pollock JS, Pollock DM. Long-Term Endothelin-A Receptor Antagonism Provides Robust Renal Protection in Humanized Sickle Cell Disease Mice. J Am Soc Nephrol. 2017 Aug; 28(8):2443-2458.
Score: 0.378
-
Elsherif L, Tang Y, Patillo KL, Wichlan D, Ogu UO, Landes K, McCune P, Scott LC, Gulledge W, Woodland WH, Nelson M, Loehr LR, Cronin RM, Desai PC, Zhou LY, Pollock DM, Zou F, Cai J, Derebail VK, Ataga KI. Association of biomarkers of endothelial function, coagulation activation and kidney injury with persistent albuminuria in sickle cell anaemia. Br J Haematol. 2024 Nov; 205(5):1963-1973.
Score: 0.158
-
Sparkenbaugh EM, Kasztan M, Henderson MW, Ellsworth P, Davis PR, Wilson KJ, Reeves B, Key NS, Strickland S, McCrae K, Pollock DM, Pawlinski R. High molecular weight kininogen contributes to early mortality and kidney dysfunction in a mouse model of sickle cell disease. J Thromb Haemost. 2020 09; 18(9):2329-2340.
Score: 0.120
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|